Skip to main content

Table 1 Clinical characteristics of the patients

From: Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA

Patient classification

All patients

(N = 50)

EGFR-TKI naïve patients (N = 32)

EGFR-TKI acquired-resistance patients (N = 18)

Age, year, median (IQR)

67.5 (59.8–73.3)

68.5 (58.3–73.8)

67.5 (62.7–73.5)

Sex, female

25 (50.0%)

14 (43.8%)

11 (61.1%)

Smoking status

 Non-smoker

25 (50.0%)

13 (40.6%)

12 (66.7%)

 Ex-smoker

14 (28.0%)

9 (28.1%)

5 (27.8%)

 Current smoker

11 (22.0%)

10 (31.3%)

1 (5.6%)

Tumor EGFR mutation

 Exon 19 deletion

22 (44.0%)

10 (31.3%)

12 (66.7%)

 L858R

15 (30.0%)

9 (28.1%)

6 (33.3%)

 Wild-type

13 (26.0%)

13 (40.6%)

0

Histology

 Adenocarcinoma

50

32

18

  1. EGFR-TKI epidermal growth factor receptor tyrosine kinase inhibitor; IQR interquartile range